Use of the asthma control questionnaire to predict future risk of asthma exacerbation

Journal of Allergy and Clinical Immunology

Volumn 127, Issue 1, 2011, Pages 167-172

  Meltzer, Eli O ^a   Busse, William W ^b   Wenzel, Sally E ^c   Belozeroff, Vasily ^d   Weng, Haoling H ^d   Feng, Jingyuan ^d   Chon, Yun ^d   Chiou, Chiun Fang ^d   Globe, Denise ^d   Lin, Shao Lee ^d  

^a ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d AMGEN INC   (United States)

Author keywords

ACQ score; antagonist; asthma control; asthma exacerbation; IL 4 receptor ; prediction

Indexed keywords

AMG 317; ANTIASTHMATIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FLUTICASONE PROPIONATE; INTERLEUKIN 4 RECEPTOR ALPHA; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ALLERGIC ASTHMA; ARTICLE; ASTHMA CONTROL QUESTIONNAIRE; ASTHMA CONTROL QUESTIONNAIRE 5; ASTHMA CONTROL QUESTIONNAIRE 6; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCORING SYSTEM; SPIROMETRY; TREATMENT DURATION; TREATMENT OUTCOME; WHEEZING;

ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MULTICENTER STUDIES AS TOPIC; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 78650859909     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2010.08.042     Document Type: Article

References (27)

1. M. Masoli, D. Fabian, S. Holt, and R. Beasley The global burden of asthma: executive summary of the GINA Dissemination Committee report Allergy 59 2004 469 478
2. K.B. Weiss, S.D. Sullivan, and C.S. Lyttle Trends in the cost of illness for asthma in the United States, 1985-1994 J Allergy Clin Immunol 106 2000 493 499
3. Asthma insight and management. 2009. Available at: http://www. takingaimatasthma.com/survey-results.html. Accessed March 9, 2010.
4. A.L. Fuhlbrigge, R.J. Adams, T.W. Guilbert, E. Grant, P. Lozano, and S.L. Janson The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines Am J Respir Crit Care Med 166 2002 1044 1049
5. C.K. Lai, T.S. De Guia, Y.Y. Kim, S.H. Kuo, A. Mukhopadhyay, and J.B. Soriano Asthma control in the Asia-Pacific region: the Asthma Insights and Reality in Asia-Pacific Study J Allergy Clin Immunol 111 2003 263 268
6. K.F. Rabe, P.A. Vermeire, J.B. Soriano, and W.C. Maier Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study Eur Respir J 16 2000 802 807
7. K.R. Chapman, L.P. Boulet, R.M. Rea, and E. Franssen Suboptimal asthma control: prevalence, detection and consequences in general practice Eur Respir J 31 2008 320 325
8. M.R. Partridge, T. van der Molen, S.E. Myrseth, and W.W. Busse Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study BMC Pulm Med 6 2006 13
9. S.P. Peters, C.A. Jones, T. Haselkorn, D.R. Mink, D.J. Valacer, and S.T. Weiss Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national Web-based survey J Allergy Clin Immunol 119 2007 1454 1461
10. E.D. Bateman, H.A. Boushey, J. Bousquet, W.W. Busse, T.J. Clark, and R.A. Pauwels Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study Am J Respir Crit Care Med 170 2004 836 844
11. Global Initiative for Asthma (GINA). GINA report: global strategy for asthma management and prevention. 2009. Available at: http://www.ginasthma.org. Accessed February 17, 2010.
12. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert Panel report 3: guidelines for the diagnosis and management of asthma. 2007. Available at: http://www.nhlbi.nih.gov/guidelines/ asthma/asthgdln.pdf. Accessed August 28, 2007.
13. H.K. Reddel, D.R. Taylor, E.D. Bateman, L.P. Boulet, H.A. Boushey, and W.W. Busse An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice Am J Respir Crit Care Med 180 2009 59 99
14. B.T. Kitch, A.D. Paltiel, K.M. Kuntz, D.W. Dockery, J.P. Schouten, and S.T. Weiss A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up Chest 126 2004 1875 1882
15. E.F. Juniper, P.M. O'Byrne, G.H. Guyatt, P.J. Ferrie, and D.R. King Development and validation of a questionnaire to measure asthma control Eur Respir J 14 1999 902 907
16. J. Corren, W. Busse, E.O. Meltzer, L. Mansfield, G. Bensch, and J. Fahrenholz A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma Am J Respir Crit Care Med 181 2010 788 796
17. E.F. Juniper, K. Svensson, A.C. Mork, and E. Stahl Measurement properties and interpretation of three shortened versions of the asthma control questionnaire Respir Med 99 2005 553 558
18. K. Svensson, A.-C. Mork, and E.F. Juniper ACQ - is five out of seven items acceptable in large clinical studies? [Abstract] Qual Life Res 12 2003 771
19. E.F. Juniper, J. Bousquet, L. Abetz, and E.D. Bateman Identifying "well-controlled" and "not well-controlled" asthma using the Asthma Control Questionnaire Respir Med 100 2006 616 621
20. P.D. Allison Survival analysis using the SAS system: a practical guide 1995 SAS Institute Inc Cary (NC) p. 138-54
21. M. Humbert, R. Beasley, J. Ayres, R. Slavin, J. Hebert, and J. Bousquet Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE Allergy 60 2005 309 316
22. A.L. Fuhlbrigge, B.T. Kitch, A.D. Paltiel, K.M. Kuntz, P.J. Neumann, and D.W. Dockery FEV(1) is associated with risk of asthma attacks in a pediatric population J Allergy Clin Immunol 107 2001 61 67
23. A.L. Fuhlbrigge, S.T. Weiss, K.M. Kuntz, and A.D. Paltiel Forced expiratory volume in 1 second percentage improves the classification of severity among children with asthma Pediatrics 118 2006 e347 e355
24. M.L. Osborne, K.L. Pedula, M. O'Hollaren, K.M. Ettinger, T. Stibolt, and A.S. Buist Assessing future need for acute care in adult asthmatics: the Profile of Asthma Risk Study: a prospective health maintenance organization-based study Chest 132 2007 1151 1161
25. R. Sato, K. Tomita, H. Sano, H. Ichihashi, S. Yamagata, and A. Sano The strategy for predicting future exacerbation of asthma using a combination of the Asthma Control Test and lung function test J Asthma 46 2009 677 682
26. E.D. Bateman, H.K. Reddel, G. Eriksson, S. Peterson, O. Ostlund, and M.R. Sears Overall asthma control: the relationship between current control and future risk J Allergy Clin Immunol 125 2010 600 608
27. T. Haselkorn, J.E. Fish, R.S. Zeiger, S.J. Szefler, D.P. Miller, and B.E. Chipps Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study J Allergy Clin Immunol 124 2009 895 902 e1-e4